Alzheimer Disease

The FDA Advisory Committee recommended donanemab, which could lead to its approval later this year.

Here are highlights from the week in Psychiatric Times.

Eisai and Biogen announced they have initiated a rolling submission for subcutaneous Leqembi for Alzheimer disease.

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

Have you checked out the latest Translating Research Into Practice column? Let us know!

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

Alzheimer disease treatment donanemab will be delayed as the FDA plans to convene a committee meeting to evaluate the phase 3 Trailblazer-Alz 2 trial.

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

AVP-786, a drug to treat agitation associated with Alzheimer disease dementia, failed to meet the primary efficacy endpoint in a phase 3 clinical trial.

Available evidence from preclinical studies indicates that semaglutide shows promise for treating Alzheimer disease and Parkinson disease.

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.

A new study correlates reduced serotonin transporter and increased amyloid-ß deposition with cognitive deficits in mild cognitive impairment, suggesting a role for serotonergics in early Alzheimer disease.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

Biogen announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease. Is this surprising?

Biogen has officially announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease.

The candidate also aims to address neurodevelopmental and neurodegenerative disorders such as Parkinson disease and Rett syndrome.

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.

Here are some updates from the world of psychiatry throughout the month of November.

What is new in research on psychedelics?

From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.

What is new in research on dementia?

New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.

What is new in research on sleep?

Today is World Alzheimer's Day!

From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.

“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”

Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.